Immunic Earnings Estimates, EPS & Revenue | NASDAQ:IMUX

Comments

Immunic Inc Earnings Estimates

IMUXNASDAQ

Trade with Public

$1.45

0.1612.40%

At close: Mar 11, 5:00 PM EST

$1.48

0.03012.08%

After Hours: 7:56 PM EST

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

Immunic Earnings Estimates, EPS & Revenue | NASDAQ:IMUX

Immunic (IMUX) is scheduled to report Q1 earnings on May 14, 2026. Analysts estimate EPS of $-0.12 and quarterly revenue of N/A.

In the most recent quarter (Q4), Immunic reported EPS of $-0.07, beating estimates of $-0.11 by 0.36%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Immunic has beaten EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Immunic has averaged an EPS surprise of 0.30% and a revenue surprise of 0.00%.

Earnings Date

May 14

EPS Estimate

$-0.120

Quarterly Revenue Estimate

–

Annual Revenue
(as of Dec 31)

–

Immunic Earnings History

Analyze the earnings history of Immunic using advanced sorting and filters.

Immunic (IMUX) Earnings Per Share

The chart below shows Immunic's reported EPS compared to analyst estimates over recent quarters.

Immunic (IMUX) Revenue

The chart below shows Immunic's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Immunic (NASDAQ:IMUX) reporting earnings?

Immunic (IMUX) is scheduled to report earnings on May 14, 2026. The last reported earnings were for reported on February 26, 2026 for Q4.

What were the latest earnings per share (EPS) for Immunic (NASDAQ:IMUX)?

The Actual EPS was $-0.07, which beat the estimate of $-0.11.

What were Immunic’s (NASDAQ:IMUX) revenues?

The Actual Revenue was $0.00, which hit the estimate of $0.00.

People Also Watch

Molecular Partners AG

Connect Biopharma Holdings Ltd

NASDAQ:CNTB

$2.79

-7.62%

Fate Therapeutics Inc

NASDAQ:FATE

$1.23

Sangamo Therapeutics Inc

NASDAQ:SGMO

$0.43

5.03%

VTVT

Tonix Pharmaceuticals Holding Corp

Immunic Earnings Estimates, EPS & Revenue | NASDAQ:IMUX

Immunic (IMUX) is scheduled to report Q1 earnings on May 14, 2026. Analysts estimate EPS of $-0.12 and quarterly revenue of N/A.

In the most recent quarter (Q4), Immunic reported EPS of $-0.07, beating estimates of $-0.11 by 0.36%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Immunic has beaten EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Immunic has averaged an EPS surprise of 0.30% and a revenue surprise of 0.00%.

Earnings Date

May 14

EPS Estimate

$-0.120

Quarterly Revenue Estimate

–

Annual Revenue
(as of Dec 31)

–